Atom Investors’s GenMark Diagnostics, Inc GNMK Stock Holding History

Atom Investors’s Portfolio GNMK Stock Details GNMK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-14,588	Closed	-$60K	–	510
2020 Q1	$60K	Buy	+14,588	New	+$68.4K	0.01%	290

Other funds holding GNMK

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Atom Investors's GNMK Position: Q2 2020 in Review

Atom Investors sold out of GenMark Diagnostics, Inc (GNMK) in Q2 2020, closing a stake of 14,588 shares — an estimated $60K sold.

Atom Investors first reported a position in GNMK in Q1 2020 and held it in 1 quarter. The position peaked at $60K in Q1 2020. 148 funds tracked by Wall St. Rank hold GNMK as of Q2 2020.

Atom Investors reported no remaining GenMark Diagnostics, Inc position as of Q2 2020 after selling out during the quarter.
Atom Investors sold 14,588 GenMark Diagnostics, Inc shares in Q2 2020, an estimated $60K.
Atom Investors first reported a position in GenMark Diagnostics, Inc in Q1 2020 and held it in 1 quarter.
Atom Investors's GenMark Diagnostics, Inc position peaked at $60K in Q1 2020.
148 funds tracked by Wall St. Rank held GenMark Diagnostics, Inc as of Q2 2020.

Based on Atom Investors's 13F filing for Q2 2020, filed 14 Aug 2020.